About a third of lung transplant patients with cystic fibrosis receive elexacaftor-tezacaftor-ivacaftor; use is higher among ...

In July 2025, Vertex Pharmaceuticals Incorporated conducted a study is to evaluate the pharmacokinetics, safety, tolerability ...

The NHS will offer a once-daily triple therapy for cystic fibrosis to hundreds more patients, including those with rare ...

Electromed, Inc. (NYSE:ELMD) is one of the 11 Best Long Term Low Risk Stocks to Invest in. Analysts maintain a Buy rating ...

Second-quarter earnings come amid many high-level challenges for the biopharma industry. How will these five closely watched ...

One double lung transplant recipient offers advice to former UFC fighter Ben Askren after his surgery, while a doctor ...

When you use a nebulizer, the directions are simple – breathe normally. It’s true that there are steps before and after ...

Vertex Pharmaceuticals has solidified its leadership in the cystic fibrosis (CF) market through strategic innovation and ...

People with congestive heart failure, undergoing treatment for schizophrenia or who have a history of paraphilic disorders will no ...

New 3D tissue model offers a breakthrough tool for understanding and treating scleroderma and other fibrotic diseases.

In head-to-head clinical trials, ALYFTREK was non-inferior on ppFEV1 and superior in reducing sweat chloride compared to ...

Trainees are “uncomfortable” about raising concerns More than a quarter of UK medical trainees in some specialties reported feeling apprehensive or hesitant about escalating a patient to the ...